On June 7, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology,reported that Thierry Guillaudeux, Ph.D., SVP Immuno-oncology at Kineta, will participate in the virtual symposium "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond," taking place on June 18, 2021 (Press release, Kineta, JUN 7, 2021, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-vista-a-new-immune-checkpoint-in-cancer-autoimmunity-and-beyond-virtual-symposium [SID1234583660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The symposium will focus on the emerging checkpoint molecule VISTA, its function, the role it plays in several disease areas and current development programs. The event will be hosted by Randolph Noelle, Ph.D., Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth; and Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.

Presentation Details:
Dr. Guillaudeux will participate on the following panels during the Symposium:

Session Title: Discovery of Anti-VISTA Antibodies
Date/Time: June 18, 2021 from 9:50 AM to 10:35 AM Eastern Time

Session Title: VISTA Advances into Clinical Development
Date/Time: June 18, 2021 from 12:20 PM to 1:05 AM Eastern Time

To access the panel discussion please register as an attendee here: https://bit.ly/3hBzIUj

"I am pleased to participate in this exciting event", said Thierry Guillaudeux of Kineta. "VISTA is an important target that I believe has a central role in converting cold, hard-to-treat tumors into hot tumors that are more susceptible to treatment. This myeloid checkpoint has the potential to improve cancer management for patients in a variety of solid tumors,"

Kineta is developing KVA12.1, a novel anti-VISTA antibody in preclinical evaluation for the treatment of solid tumors. VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.

On June 7, 2021 NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that it will host a virtual KOL event for analysts, investors, and the scientific community on Friday, June 11, 2021 at 8AM ET / 2PM CET (Press release, Nanobiotix, JUN 7, 2021, View Source [SID1234583676]). The event will feature several key opinion leaders, including current study investigators.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Nanobiotix KOL event will provide an in-depth review of the immunotherapy data presented at the 2021 Annual Meeting of American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) along with clinical perspectives on the implications of potential first-in-class radioenhancer NBTXR3 across the oncology landscape.

Registration for the event is now open on the events section of the Company’s website. A live webcast of the discussion and an archived recording will be available on the events section as well.

Nanobiotix Virtual KOL Event Program

Can NBTXR3 Turn Anti-PD-1 Non-responders into Responders and Deepen Response in Naïve Patients?

Agenda:

Opening Remarks (8:00AM ET / 2:00PM CET)
Presented by Jeffrey Bockman, PhD, EVP and Oncology Practice Head, Cello Health BioConsulting
NBTXR3 Mode of Action (8:05AM ET / 2:05PM CET)
Presented by Laurent Levy, PhD, co-founder and CEO, Nanobiotix
Overview of the Treatment Landscape: Promise and Limitations of Immunotherapy, and Rationale for Combination-based Approaches (8:10AM ET / 2:10PM CET)
Presented by Jared Weiss, MD, Associate Professor of Medicine, Division of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center
Nanobiotix Study 1100 Safety and Efficacy Data Update (8:20AM ET / 2:20PM CET)
Presented by Tanguy Seiwert, MD, Assistant Professor of Oncology, Director, Head and Neck Cancer Oncology Disease Group, Johns Hopkins Medicine and Colette Shen, MD, PhD, Assistant Professor, Radiation Oncology, University of North Carolina Lineberger Comprehensive Cancer Center
NBTXR3 as a Potential Combination-agnostic Product, Rationale, and Future Opportunity (8:40AM ET / 2:20PM CET)
Presented by James Welsh, MD, Associate Professor, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center
Discussion and Q&A, Implications of Study 1100 in Head and Neck Cancer and Beyond (8:50AM ET / 2:50PM CET)
Panel Discussion Moderated by Jeffrey Bockman
Summary Close (9:10AM ET / 3:10PM CET)
Presented by Jeffrey Bockman

On June 7, 2021 Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, reported that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") to provide up to $35.0 million in term loans (Press release, Cerecor, JUN 7, 2021, View Source [SID1234583693]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to partner with Horizon, a leading specialty finance company that has an extensive history of supporting innovative life science companies," said Michael Cola, Chief Executive Officer of Cerecor. "Over the course of 2021, we anticipate a number of important data readouts across our immunology, oncology, and rare genetic disorders product candidates. This transaction immediately strengthens and extends our financial resources to advance our clinical pipeline towards these key development milestones."

Gerald A. Michaud, President of Horizon stated, "We are delighted to provide this financing to Cerecor and have confidence in the Company’s business strategy. We look forward to watching the Company reach its critical development milestones for its orphan and rare disease therapies in the pipeline. This investment in Cerecor provides another example of our ability to finance life sciences companies through multiple stages of development and through various value inflection points."

$20 million of the $35 million loan was funded upon closing. The remaining $15 million may be funded upon Cerecor achieving certain predetermined milestones. Each advance of the loan will be repaid in 42 monthly payments consisting of 18 monthly payments of interest only, followed by 24 monthly payments of principal and accrued interest, and will be payable monthly in arrears. The interest-only period may be extended to 24 months contingent upon Cerecor achieving certain milestones. In connection with the financing, Cerecor issued Horizon warrants to purchase up to 403,844 of its common shares at an exercise price of $2.60 per share. Proceeds will be used to support the ongoing clinical development of key investigational product candidates within its pipeline and for general working capital purposes.

Jefferies acted as exclusive arranger and financial advisor to Cerecor in this transaction.

On June 7, 2021 Almac Group, the global contract pharmaceutical development and manufacturing organisation, has reported a £43 million (6%) rise in turnover from £634.3 million in 2018/19 to £677.3 million for its financial year 2019/20 (Press release, Almac, JUN 7, 2021, View Source [SID1234583645]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During this period, the revenue increase resulted in improved pre-tax profits which were recorded at £63.5 million, up from £47.6 million for the same period the previous year. Group performance in 2020 was enhanced through the receipt of a number of out-licencing payments from products developed in-house.

Average employee figures increased from 5,150 to 5,466 during the same period. These figures were recorded in the organisation’s annual report for year ending 30 September 2020.

Throughout this year, Almac invested significantly in both new and existing facilities to meet ongoing global demand for its unique, high-quality solutions. In addition, the Group completed the acquisition of Swedish-based boutique healthcare company, POA Pharma, which added substantial new therapeutic areas and territories to its existing Galen portfolio.

As the race for a vaccine and treatment for COVID-19 escalated, Almac partnered with a variety of global pharmaceutical, biotech and research institutions to support over 140 separate crucial research projects through a range of service areas, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support and clinical trial management.

Alan Armstrong, Almac Group CEO, commented: "The last financial year was challenging for everyone as companies, including Almac, had to adapt much of their typical operational practices in response to the pandemic whilst ensuring the safest working environment for employees. I am extremely proud of Almac’s efforts to ensure client service levels were not impacted in any way throughout and ensuring patients received the medication they so depend upon. The commitment, dedication and professionalism from our employees has been exemplary and I wish to thank them all.

He continued: "Almac’s mission is to "advance human health" and this has never been more applicable than right now as we continue to support multiple companies in their quest to make significant advances in the fight against COVID and other diseases. With 100% of our profits reinvested into our business, we have already committed to a number of significant expansion and improvement projects across our sites in the US, Europe and Asia in order to ensure we provide the premium solutions our global client base rely on."

On June 7, 2021 Thermo Fisher Scientific, the world leader in serving science, and Advanced Electrophoresis Solutions Ltd (AES), specialists in protein imaging technologies, reported an agreement to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization (Press release, Lifescience Newswire, JUN 7, 2021, View Source [SID1234583661]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Together, the companies will promote Thermo Fisher’s expertise as a leading provider of mass spectrometry technology for biopharma and proteomics applications, and AES’ ability to provide high performing whole column imaging detection capillary electrophoresis systems for protein separation, quantification and characterization. The companies will highlight the strengths of their technologies when coupled for protein analysis to provide laboratories with new and advanced biopharmaceutical capabilities that will enable greater insight into results generated by Imaged Capillary Isoelectric Focusing (iCIEF) protein separation. This will be of particular benefit to scientists working in the areas of biopharma, clinical, food analysis and academia.

"Protein separation, purification and analysis are crucial components in biotherapeutic development, but the process can be complex and challenging," said Eric Grumbach, director, pharma/biopharma, chromatography and mass spectrometry, Thermo Fisher Scientific. "While mass spectrometry does provide high-sensitivity and high-resolution protein mass information, there are cases where insight from a different angle is required. Through this agreement we will pair our technology with more widely used and essential separation tools previously not routinely coupled to MS to make protein variant identification easier and more accurate to advance high-quality information and scientific knowledge."

Tiemin Huang, CEO, AES, said, "There is a growing demand for proteomics and protein characterization, driven by the rise of personalized medicine, so it’s important that the best combination of tools are available to progress our understanding and research in this important field. By working side-by-side with Thermo Fisher to combine high resolution accurate mass-mass spectrometry (HRAM-MS) with alternative protein separation techniques, we will support our customers to achieve more precise analyses that will play a significant role in the continued development of effective therapeutics."

Thermo Fisher Scientific will showcase its newest products, software solutions and collaborations in a company-hosted virtual event, "Innovation Summit: Shaping the Future of LC-MS in Life Science Together," from June 8-10, 2021. Register here to learn more.